US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

48.03

+0.36000.76%

Post-market: 48.030.00000.00%19:30 EDT

Volume:437.29K

Turnover:20.95M

Market Cap:14.69B

PE:21.54

High:48.34

Open:47.74

Low:47.58

Close:47.67

52wk High:55.49

52wk Low:46.87

Shares:305.78M

Float Shares:305.78M

Volume Ratio:1.18

T/O Rate:0.14%

Dividend:2.06

Dividend Rate:4.28%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.62

PE(LYR):19.48

Loading ...

Overview Company News Filings

Emera Raises Quarterly Dividend at CA$0.74 a Share From CA$0.7325

MT Newswires Live

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

Press Release: MaaT Pharma Publishes Its Half-Year 2026 Results and Provides a Business Update

Fastest megawatt is the winning megawatt: Tan See Leng

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

Top 4 S-REITs Raising DPU by 10% or More

The Smart Investor

Forget Banks: 3 S-REITs Surprising Unitholders with Higher DPUs

The Smart Investor

Dozens of Patients Take Legal Action Against Maker of Semaglutide

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances

MaaT Pharma Faces EMA Setback on Microbiome Therapy for aGvHD

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Emera (EMA) Gets a Hold from J.P. Morgan

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

Japan Breakthrough Hands Shiba Inu (SHIB) Big Win in August, but September Threat Looms

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/EMA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":48.03,"timestamp":1790971200000,"preClose":47.67,"halted":0,"volume":437290,"hourTrading":{"tag":"盘后","latestPrice":48.03,"preClose":48.03,"latestTime":"19:30 EDT","volume":13010,"amount":624820.919633,"timestamp":1790983804986,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007551919446192562,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Market Closed","change":0.36,"latestTime":"10-02 16:00:00 EDT","open":47.74,"high":48.34,"low":47.58,"amount":20947357.68972,"amplitude":0.015943,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":47.67,"dividendRate":0.042821,"postHourTrading":{"tag":"盘后","latestPrice":48.03,"preClose":48.03,"latestTime":"19:30 EDT","volume":13010,"amount":624820.919633,"timestamp":1790983804986,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1806752549615969,"impliedVol":0.3585,"impliedVolPercentile":0.9004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.1806752549615969,"shares":305783111,"dividePrice":2.0567,"high":48.34,"amplitude":0.015943,"preClose":47.67,"low":47.58,"week52Low":46.87,"pbRate":"1.62","psRate":"2.34","week52High":55.49,"institutionHeld":0,"latestPrice":48.03,"eps":2.229761,"divideRate":0.042821,"volume":437290,"delay":0,"ttmEps":2.229761,"open":47.74,"prevYearClose":49.24,"prevWeekClose":47.73,"prevMonthClose":47.83,"prevQuarterClose":47.83,"fiveDayClose":47.73,"twentyDayClose":50.3,"sixtyDayClose":53.16,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-10-02","current":21.540425,"percent":0.410714,"low":16.637027,"twenty":18.01228,"median":20.227938,"eighty":21.00586,"high":22.07626,"avg":19.838823,"sd":1.446483,"marketCap":14620461610.8},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33},{"date":"2026-09-18","current":20.381538,"twenty":17.871551,"median":20.245144,"eighty":21.031403,"marketCap":15149228130.36},{"date":"2026-09-25","current":19.941415,"twenty":17.94243,"median":20.238018,"eighty":21.011747,"marketCap":14658867103.01},{"date":"2026-10-02","current":20.032985,"twenty":18.01228,"median":20.227938,"eighty":21.00586,"marketCap":14620461610.8}],"updateTime":1791093364212},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672746505","title":"Emera Raises Quarterly Dividend at CA$0.74 a Share From CA$0.7325","url":"https://stock-news.laohu8.com/highlight/detail?id=2672746505","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672746505?lang=en_us&edition=fundamental","pubTime":"2026-10-03 03:16","pubTimestamp":1790968560,"startTime":"0","endTime":"0","summary":"Price: 47.86, Change: +0.19, Percent Change: +0.40","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672792573","title":"Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672792573","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672792573?lang=en_us&edition=fundamental","pubTime":"2026-10-02 14:00","pubTimestamp":1790920800,"startTime":"0","endTime":"0","summary":"BASEL, Switzerland, Oct.  02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3373510/20739/en/ultragenyx-announces-marketing-authorisation-application-maa-submission-to-the-european-medicines-agency-ema-for-the-first-investigational-gene-therapy-for-mps-iiia-sanfilippo-synd.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","EMA","BK4585","SPRE","BK4215","BK4081","BK4588","MDCO","MAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671245482","title":"Press Release: MaaT Pharma Publishes Its Half-Year 2026 Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2671245482","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671245482?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:00","pubTimestamp":1790697600,"startTime":"0","endTime":"0","summary":"--  In September 2026, following the re-examination procedure, the. CHMP maintained its negative opinion on the Conditional Marketing. --  Feedback received through a Type C interaction with the U.S.Food and Drug Administration  contributes to the preparation. of PHOENIX as a proposed registrational Phase 3 trial and provides. a framework for finalizing the protocol and progressing U.S.H1 2025, mostly driven by the impact of the Clinigen Licensing Agreement. as of January 1, 2026, while patient demand in the Early Access Program. --  Cash runway now estimated to extend to December 2026 based on the. authorizations have been given under the Early Access Program in 14. --  In March 2026, at the European Society for Blood and Marrow. results from the ARES trial evaluating MaaT013  in aGvHD.The Company also presented CHRONOS real-world data, reporting 29%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772923.USD","BK4022","TM","03160","BK4555","BK4099","LU1496350502.SGD","MET","SPRE","R","LU1989772840.SGD","BK4585","BK4232","BK4588","BK4604","LU1291159041.SGD","LU1989771016.USD","IND","BK4081","BK4162","BK4215","BK4211","MAA","EMA","EBMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671694042","title":"Fastest megawatt is the winning megawatt: Tan See Leng","url":"https://stock-news.laohu8.com/highlight/detail?id=2671694042","media":"Lin Daoyi","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671694042?lang=en_us&edition=fundamental","pubTime":"2026-09-28 05:00","pubTimestamp":1790542800,"startTime":"0","endTime":"0","summary":"\"Singapore's peak electricity demand is projected to grow at a faster pace in the coming years, driven by advanced manufacturing, digital economy and transport electrification.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/news/energy/fastest-megawatt-winning-megawatt-tan-see-leng?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/energy/fastest-megawatt-winning-megawatt-tan-see-leng?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["BK4182","BK4081","EMA","BESS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461514","title":"MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461514","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669461514?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:00","pubTimestamp":1790244000,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Sept.  24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchang","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368112/7767/en/medicinova-announces-completion-of-last-patient-last-visit-in-the-double-blind-portion-of-the-phase-2b-3-combat-als-trial-of-mn-166-ibudilast.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","LU0210528500.USD","IE00B3S45H60.SGD","CAFS","LU0106831901.USD","LU1244550221.USD","LU2089283258.USD","LU1989772840.SGD","LU1720051017.SGD","LU0320765646.SGD","IAI","LU0234570918.USD","LU1162221912.USD","LU1732800096.USD","LU2264538146.SGD","LU1244550577.SGD","BMED","KBWB","LU2111349929.HKD","ARDS","LU0795875086.SGD","MEDX","LU0882574139.USD","EMA","BK4581","BK4588","LU2023251221.USD","LU1363072403.SGD","LU0006306889.USD","LU0557290698.USD","LU2357305700.SGD","IDNA","GDOC","NVIB","HYLG","LU0314104364.USD","MNOV","LU0528227936.USD","LU0795875169.SGD","LU1988902786.USD","LU0053666078.USD","LU0912757837.SGD","BK4516","LU0106261372.USD","LU0971096721.USD","LU2133065610.SGD","BK4504","LU0158827781.USD","IE00BKVL7J92.USD","LU0225283273.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669562483","title":"Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening","url":"https://stock-news.laohu8.com/highlight/detail?id=2669562483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669562483?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:47","pubTimestamp":1790164020,"startTime":"0","endTime":"0","summary":"- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/23/3367401/0/en/acoramidis-demonstrates-real-world-benefit-versus-tafamidis-in-attr-cm-reducing-risk-of-clinical-worsening.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATTR","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669745011","title":"Top 4 S-REITs Raising DPU by 10% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2669745011","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669745011?lang=en_us&edition=fundamental","pubTime":"2026-09-23 11:30","pubTimestamp":1790134200,"startTime":"0","endTime":"0","summary":"Four S-REITs raised DPU by 10% or more in 1H2026, but investors should examine what is driving each increase and whether it can last.","market":"sg","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2026/03/Parkway-life-REIT-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2026/03/Parkway-life-REIT-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/top-4-s-reits-raising-dpu-by-10-or-more/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/top-4-s-reits-raising-dpu-by-10-or-more/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["BK4139","SRU.SI","GRI","CFA","TRUR","DFRA","CRPU.SI","BK7129","YLDW","BK6014","IVRA","8C8U.SI","SRT.SI","BK6072","BK6131","BK6134","CFA.SI","BK4127","CLR.SI","REIT","RJMG","RNTY","XHOA","BK6137","IQRA","PSCF","BK4007","BK6108","C2PU.SI","BK6011","DPU","AJBU.SI","EMA.AU","TS0U.SI","RIET","BK6142","URE","JJJ.SI","GLS.SI","BK4081","BK6512","BPRE","MDIV","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669196097","title":"Forget Banks: 3 S-REITs Surprising Unitholders with Higher DPUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669196097","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669196097?lang=en_us&edition=fundamental","pubTime":"2026-09-22 07:30","pubTimestamp":1790033400,"startTime":"0","endTime":"0","summary":"Three S-REITs beyond the blue chips raised DPU in 1H2026, but investors should assess whether these higher distributions can continue.","market":"nz","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2026/09/Sasseur-REITHefei-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2026/09/Sasseur-REITHefei-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/forget-banks-3-s-reits-surprising-unitholders-with-higher-dpus/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/forget-banks-3-s-reits-surprising-unitholders-with-higher-dpus/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["RIET","IVRA","RNTY","TS0U.SI","EMA","TRUR","BK7129","CFA","DFRA","BK6512","URE","BK6011","GRI","BK6142","CLR.SI","DPU","BK6072","REIT","SRU.SI","BK6137","SRT.SI","CFA.SI","JJJ.SI","ODBU.SI","XHOA","RJMG","BK4007","PSCF","MDIV","EMA.AU","BK4081","BPRE","BK4127","YLDW","8C8U.SI","BK4139","IQRA","GLS.SI","CRPU.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191567475","title":"Dozens of Patients Take Legal Action Against Maker of Semaglutide","url":"https://stock-news.laohu8.com/highlight/detail?id=1191567475","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191567475?lang=en_us&edition=fundamental","pubTime":"2026-09-20 15:41","pubTimestamp":1789890089,"startTime":"0","endTime":"0","summary":"Renowned for its role in managing type 2 diabetes and aiding weight control, the blockbuster weight-loss medication semaglutide has seen robust sales worldwide, yet its potential side effects are...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA","AOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668924809","title":"Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668924809","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668924809?lang=en_us&edition=fundamental","pubTime":"2026-09-18 22:51","pubTimestamp":1789743060,"startTime":"0","endTime":"0","summary":"If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroidsRecommendation based on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/18/3364794/0/en/novartis-receives-positive-chmp-opinion-for-cosentyx-in-polymyalgia-rheumatica-pmr.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081","BK4202","AS","PMR","BK4201","EC","BK4087","CHMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667626074","title":"Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2667626074","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667626074?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:46","pubTimestamp":1789490810,"startTime":"0","endTime":"0","summary":"Aelis Farma SA ( ($FR:AELIS) ) has provided an update. In the first half of 2026, Aelis Farma advanced its clinical priorities, most notably the in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aelis-farma-secures-key-ema-backing-and-extends-cash-runway-as-cb1-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aelis-farma-secures-key-ema-backing-and-extends-cash-runway-as-cb1-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667611371","title":"MaaT Pharma Faces EMA Setback on Microbiome Therapy for aGvHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2667611371","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667611371?lang=en_us&edition=fundamental","pubTime":"2026-09-15 14:20","pubTimestamp":1789453234,"startTime":"0","endTime":"0","summary":"MaaT Pharma ( ($FR:MAAT) ) has issued an update. MaaT Pharma announced that the European Medicines Agency’s CHMP has signaled a negative trend in i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maat-pharma-faces-ema-setback-on-microbiome-therapy-for-agvhd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maat-pharma-faces-ema-setback-on-microbiome-therapy-for-agvhd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPV","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666585879","title":"Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666585879","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666585879?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:00","pubTimestamp":1788940800,"startTime":"0","endTime":"0","summary":"- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events St","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358343/0/en/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-children-with-achondroplasia-in-the-phase-3-propel-3-trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","AHI","BK4097","BK4167","BK4585","EMA","BK4081","SPRE","BK4215","BK4588","MAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320770","title":"Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320770","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320770?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:20","pubTimestamp":1788870000,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","LU2065732104.USD","BK4097","COAL","BK4081","CANF","BK4139","BK4006","PRGS","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811530","title":"Emera (EMA) Gets a Hold from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811530?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:18","pubTimestamp":1788351522,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Eli Jossen maintained a Hold rating on Emera yesterday and set a price target of C$75.00. The company’s shares closed yesterday...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/emera-ema-gets-a-hold-from-j-p-morgan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/emera-ema-gets-a-hold-from-j-p-morgan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","LU1548497426.USD","LU1720051108.HKD","LU1989772923.USD","LU2133065610.SGD","IAI","LU1791710400.SGD","LU2028103732.USD","LU2357305700.SGD","LU1244550577.SGD","LU0912757837.SGD","BK4516","LU0557290698.USD","LU1732800096.USD","LU0528227936.USD","LU0320765646.SGD","LU1162221912.USD","LU1064131342.USD","LU1732799900.SGD","KBWB","LU0882574139.USD","LU1244550221.USD","EMA","IE00BZ1G4Q59.USD","BK4581","LU1668664300.SGD","LU1074936037.SGD","LU1244550494.USD","LU0795875086.SGD","BK4534","LU2023251221.USD","LU0234570918.USD","LU2111349929.HKD","IE00B775SV38.USD","LU0210528500.USD","LU2089284900.SGD","LU2271345857.HKD","IE00BKVL7J92.USD","LU0158827948.USD","LU2347655156.SGD","LU1988902786.USD","LU0225283273.USD","LU0267386448.USD","BK4588","LU0390134368.USD","LU0106831901.USD","LU2487616109.SGD","LU1989772840.SGD","BK4585","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663004445","title":"Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM","url":"https://stock-news.laohu8.com/highlight/detail?id=2663004445","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663004445?lang=en_us&edition=fundamental","pubTime":"2026-08-30 22:00","pubTimestamp":1788098400,"startTime":"0","endTime":"0","summary":"- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging,with up to half of patients showing ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/30/3352965/0/en/acoramidis-demonstrates-reversal-of-cardiac-structural-disease-progression-and-functional-decline-and-significantly-increases-days-alive-and-free-from-hospitalization-in-attr-cm.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVM","ACM","LU0124676726.USD","LU2238339852.HKD","LU0187121727.USD","LU1861214812.USD","ATTR","LU0689626769.HKD","LU1861219969.SGD","LU2298064838.USD","EMA","LU1939255532.USD","AIPO","LU2360107325.USD","LU2308191902.HKD","CHAT","BK4139","AGIX","BK4516","ARTY","BK4081","LU2244417387.USD","QTOC","BK4129","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662009803","title":"Japan Breakthrough Hands Shiba Inu (SHIB) Big Win in August, but September Threat Looms","url":"https://stock-news.laohu8.com/highlight/detail?id=2662009803","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662009803?lang=en_us&edition=fundamental","pubTime":"2026-08-27 12:40","pubTimestamp":1787805600,"startTime":"0","endTime":"0","summary":"TheShiba Inu (SHIB) meme token is ending the month with an all-time record August return, confirming a break in its long-term downtrend. However, the asset's historical vulnerability to September seas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/japan-breakthrough-hands-shiba-inu-shib-big-win-in-august-but-september-threat-looms","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/japan-breakthrough-hands-shiba-inu-shib-big-win-in-august-but-september-threat-looms","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["EMA","BK4081","FSA.AU","EMA.AU","BK7093","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759746","title":"U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759746","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763540,"startTime":"0","endTime":"0","summary":"RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent syste","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351615/0/en/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","L","EMA","BBH","BK4605","HR","LU0320765992.SGD","ON","LU1978683503.SGD","BK4141","BK4585","LU1854103824.USD","LU2487616109.SGD","PFS","BK4009","IE00BD6J9T35.USD","LU0053671581.USD","ONG","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0724618433.USD","LU1861219969.SGD","SRET","LU1861220033.SGD","LU1720051108.HKD","LU2360107325.USD","BK4512","LU0109394709.USD","LU1720051017.SGD","BK4225","LU0210528500.USD","IDNA","RVMD","BK4613","IE0009354923.USD","BK4023","LU0124384867.USD","IE00BZ199S13.USD","LABU","BK4588","ITT","PTH","BK4139","TTD","ONX","TTDU","IE0009355771.USD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275001","title":"BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275001","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275001?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:30","pubTimestamp":1787571000,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., Aug.  24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic cond","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349646/0/en/bridgebio-to-present-new-acoramidis-data-from-open-label-extension-analyses-in-attr-cm-at-esc-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","CM","BK4081","ATTR","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661022177","title":"First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2661022177","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661022177?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:00","pubTimestamp":1787558400,"startTime":"0","endTime":"0","summary":"The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349489/0/en/first-patient-treated-in-pioneer-1-registrational-trial-of-privosegtor-for-optic-neuritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ON","BK4127","LU0724618433.USD","LU2028103732.USD","KBWB","IE00BD6J9T35.USD","LU0912757837.SGD","LU1989772923.USD","LU0225283273.USD","LU0158827948.USD","LU1244550494.USD","LU1791710582.SGD","IE00BZ199S13.USD","BK4588","LU2089284900.SGD","LU1244550221.USD","IE00B775SV38.USD","LU1861220033.SGD","LU2089283258.USD","LU0882574139.USD","LU1983260115.SGD","LU2298322129.HKD","LU1720051017.SGD","LABU","LU0528227936.USD","ONG","IE00BZ1G4Q59.USD","LU0106261372.USD","LU1978683503.SGD","LU1854103824.USD","IE00B3S45H60.SGD","LU0795875086.SGD","LU1074936037.SGD","LU0267386448.USD","LU0053666078.USD","LU0390134368.USD","LU2347655156.SGD","LU0098860793.USD","IAI","LU0348723411.USD","LU0234570918.USD","BK4504","LU1668664300.SGD","BK4081","EMA","BK4141","LU1732799900.SGD","ONX","BK4581","LU1732800096.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}